Sepsis - Pipeline Review, Q2 2011

Global Markets Direct, April 2011, Pages: 104

Sepsis - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Sepsis - Pipeline Review, Q2 2011', provides an overview of the Sepsis therapeutic pipeline. This report provides information on the therapeutic development for Sepsis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sepsis. 'Sepsis - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Sepsis.
- A review of the Sepsis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Sepsis pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Sepsis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Sepsis pipeline depth and focus of Sepsis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Sepsis Overview
Therapeutics Development
An Overview of Pipeline Products for Sepsis
Sepsis Therapeutics under Development by Companies
Sepsis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Sepsis Therapeutics - Products under Development by Companies
Sepsis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Sepsis Therapeutics Development
Genzyme Corporation
Medinox, Inc.
Sanofi-Aventis
AstraZeneca PLC
GlaxoSmithKline plc
Daiichi Sankyo Company, Ltd
Cytokine PharmaSciences, Inc.
Chong Kun Dang Pharmaceutical
Eisai Co., Ltd.
Lorus Therapeutics Inc
Lpath, Inc.
Compugen Ltd.
CytoGenix, Inc.
Am-Pharma B.V.
Artisan Pharma, Inc.
Exponential Biotherapies, Inc.
Atox Bio Inc.
Cornerstone Therapeutics Inc.
Biosynexus Incorporated
NexBio, Inc.
Ikaria Inc.
Endacea, Inc.
Ferring Pharmaceuticals, Inc.
Kemin Industries, Inc.
Agennix AG
Sepsis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
E5564 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Talactoferrin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pagibaximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Norepinephrine + Dobutamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epinephrine for Septic Shock (University of Versailles) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cefazolin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hydrocortisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cotrimoxazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Terlipressin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Arginine vasopressin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Activated Protein C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hydrocortisone + Fludrocortisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant human activated protein C + Hydrocortisone + Fludrocortisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dopamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Norepinephrine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dopamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Norepinephrine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Insulin + Hydrocortisone + Fludrocortisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Insulin + Hydrocortisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ibuprofen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Procaine Penicillin + Gentamicin + Amoxicillin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Terlipressin + Dopamine + Norepinephrine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hydrocortisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
hydrocortisone sodium succinate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rosuvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Simvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ciprofloxacin + Co-Amoxyclav - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chlorhexidine Gluconate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hydrocortisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hypertonic Saline + Terlipressin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tetraspan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sepsis Therapeutics – Drug Profile Updates
Sepsis Therapeutics - Discontinued Products
Sepsis - Featured News
Jan 17, 2011: Agennix Announces Longer-Term Mortality Data From Talactoferrin Phase II Trial In Severe Sepsis Presented At 40th Critical Care Congress
Jan 12, 2011: Agennix To Present Talactoferrin Phase II Trial Data In Severe Sepsis At 40th Critical Care Congress Of Society Of Critical Care Medicine
Oct 25, 2010: AstraZeneca Initiates Phase IIB Study For AZD9773 As Treatment For Severe Sepsis
Oct 25, 2010: Intercell Announces Positive Results From Phase II Pseudomonas Aeruginosa Investigational Vaccine Study For Certain Hospital-Acquired Infections
Sep 14, 2010: Atox Bio Announces Dosing Of First Subject In Phase I Study Of AB103
Sep 03, 2010: Agennix Presents Data On Talactoferrin Phase II Trial In Severe Sepsis At Sepsis 2010 International Symposium
May 12, 2010: Agennix Announces Upcoming Data Presentation From Talactoferrin Phase II Trial In Severe Sepsis At Ats
Apr 09, 2010: XOMA To Present Data On XOMA 052 At American Association of Cancer Research Annual Meeting
Apr 09, 2010: XOMA To Present Data On XOMA 052 At American Association of Cancer Research Annual Meeting
Mar 25, 2010: Eisai To Continue Eritoran Phase III Severe Sepsis Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Sepsis, Q2 2011
Products under Development for Sepsis – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Genzyme Corporation, 2011
Medinox, Inc., 2011
Sanofi-Aventis, 2011
AstraZeneca PLC, 2011
GlaxoSmithKline plc, 2011
Daiichi Sankyo Company, Ltd, 2011
Cytokine PharmaSciences, Inc., 2011
Chong Kun Dang Pharmaceutical, 2011
Eisai Co., Ltd., 2011
Lorus Therapeutics Inc, 2011
Lpath, Inc., 2011
Compugen Ltd., 2011
CytoGenix, Inc., 2011
Am-Pharma B.V., 2011
Artisan Pharma, Inc., 2011
Exponential Biotherapies, Inc., 2011
Atox Bio Inc., 2011
Cornerstone Therapeutics Inc., 2011
Biosynexus Incorporated, 2011
NexBio, Inc., 2011
Ikaria Inc., 2011
Endacea, Inc., 2011
Ferring Pharmaceuticals, Inc., 2011
Kemin Industries, Inc., 2011
Agennix AG, 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Sepsis Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Sepsis, Q2 2011
Products under Development for Sepsis – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Discovery and Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Customers who bought this item also bought

• Sepsis - Pipeline Review, Q4 2010
• Blood Coagulation - Pipeline Review, H2 2012
• Shock - Pipeline Review, H2 2012
• Fatty Liver Disease - Pipeline Review, H2 2012
• Sepsis Partnering 2007-2013
• Nausea - Pipeline Review, H2 2012
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Ageing - Pipeline Review, H2 2012
• Burns - Pipeline Review, H1 2013
• Other Hematological Disorders - Pipeline Review, H2 2012